

SCIENTIFIC REPORTS



OPEN

A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins

Received: 23 August 2016
Accepted: 25 November 2016
Published: 11 January 2017

Tobias G. Kapp¹, Florian Rechenmacher¹, Stefanie Neubauer¹, Oleg V. Maltsev¹, Elisabetta A. Cavalcanti-Adam², Revital Zarka³, Ute Reuning⁴, Johannes Notni⁵, Hans-Jürgen Wester⁵, Carlos Mas-Moruno⁶, Joachim Spatz², Benjamin Geiger³ & Horst Kessler¹

Integrins, a diverse class of heterodimeric cell surface receptors, are key regulators of cell structure and behaviour, affecting cell morphology, proliferation, survival and differentiation. Consequently, mutations in specific integrins, or their deregulated expression, are associated with a variety of diseases. In the last decades, many integrin-specific ligands have been developed and used for modulation of integrin function in medical as well as biophysical studies. The IC_{50} -values reported for these ligands strongly vary and are measured using different cell-based and cell-free systems. A systematic comparison of these values is of high importance for selecting the optimal ligands for given applications. In this study, we evaluate a wide range of ligands for their binding affinity towards the RGD-binding integrins $\alpha v\beta 3$, $\alpha v\beta 5$, $\alpha v\beta 6$, $\alpha v\beta 8$, $\alpha 5\beta 1$, $\alpha IIb\beta 3$, using homogenous ELISA-like solid phase binding assay.

Structural and signalling responses of cells are tightly regulated by multiple adhesive interactions with the pericellular microenvironment, which promotes the physical networking of neighbouring cells and physical attachment to diverse extracellular matrix (ECM) networks. In addition, multiple environmental cues are mediated via adhesion receptors that bind selectively to external ligands and activate transmembrane signaling pathways that affect cell shape, dynamics, and fate^{1–3}.

Integrins are a highly diversified class of key ECM adhesion receptors, that play essential biological functions in all higher organisms. They consist of two distinct transmembrane subunits, one α and one β , which connect the intracellular cytoskeleton and the pericellular ECM. As bidirectional signaling machines integrins respond to environmental cues (outside-in signaling) and at the same time, transduce internal signals (e.g. mechanical stress) to the matrix (inside-out signaling), thereby playing crucial roles in cell-cell communication and ECM⁴. In 1984, Pierschbacher and Ruoslahti discovered the Arg-Gly-Asp (RGD) sequence in fibronectin as the minimal integrin binding motif⁵. Later, this sequence was found in other cell adhesive ECM proteins and described as a common cell recognition motif. These findings were readily followed by the development of multiple peptidic and non-peptidic RGD-based integrin ligands, with various degrees of specificity^{6–9}. To date, eight of the 24 known human integrin heterodimers were shown to bind the RGD-recognition sequence^{10,11}. Yet, despite their apparent similarity, these integrins can readily distinguish between different RGD-containing ECM proteins (e.g. vitronectin, fibronectin, fibrinogen etc.), and respond differently to the interaction with each one of them.

Given the involvement of integrin-mediated adhesion in the regulation of multiple physiological processes¹² (e.g. cell migration, proliferation, survival, and apoptosis) as well as pathological processes (e.g. tumor invasion, metastasis), the development of integrin sub-type-exclusive antagonists is highly desirable. Indeed, integrin

¹Institute for Advanced Study and Center for Integrated Protein Science, Department of Chemistry, Technische Universität München, Lichtenbergstr. 4, 85747 Garching, Germany. ²Max-Planck-Institute for Medical Research, Department of Biointerface Science and Technology, Heidelberg, Postal address: Heisenbergstr. 3, 70 569 Stuttgart, Germany. ³Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, 7610001, Israel. ⁴Clinical Research Unit, Department of Obstetrics & Gynecology, Technische Universität München, Ismaninger Strasse 22, 81675 Munich, Germany. ⁵Pharmaceutical Radiochemistry, Technische Universität München, Munich, Germany. ⁶Biomaterials, Biomechanics and Tissue Engineering Group, Department of Materials Science and Metallurgical Engineering, and Centre for Research in NanoEngineering (CRNE), Technical University of Catalonia, 08028-Barcelona, Spain. Correspondence and requests for materials should be addressed to H.K. (email: Kessler@tum.de)




Figure 1. Illustration of different binding modes of a linear RGD peptide to different integrin subtypes. Crystal structures of $\alpha 5\beta 1$ (top), $\alpha v\beta 3$ (middle), and $\alpha IIb\beta 3$ (bottom) in complex with RGD ligands. Figure adapted from⁴⁵.

antagonists were shown to have high therapeutic potential^{13–17}. Specifically, selective integrin ligands were widely used to target integrin-overexpressing tumors, as inhibitors of cancer angiogenesis^{18,19} and as blockers of excessive blood coagulation¹⁵. Modified integrin ligands were also used for carrying radionuclei or dyes for tumor diagnosis (using PET, SPECT or fluorescent probes)²⁰, or for functionalization of adhesive surfaces and development of cell instructive biomaterials^{21–24}.

Development of integrin subtype-selective compounds

Most ECM proteins display a very broad pattern of integrin binding activity. For example fibronectin preferentially binds to $\alpha 5\beta 1$, $\alpha v\beta 6$, $\alpha v\beta 8$ and to $\alpha IIb\beta 3$, although with different activities, while integrin $\alpha IIb\beta 3$ is primarily expressed on platelets and binds to specific adhesive proteins, such as fibrinogen/fibrin, prothrombin and plasminogen. Nevertheless, despite their narrow specificity, integrin ligands that target $\alpha IIb\beta 3$, should be used for therapeutic purposes with great care, since their excessive systemic administration might cause hemorrhagic disorders. On the other hand, short linear peptides, mimicking the RGD sequence showed a significantly lower binding to $\alpha IIb\beta 3$, and had limited effect on platelet functions⁵. A few years later, we addressed the need of focusing on high affinity ligands toward $\alpha v\beta 3$ while maintaining selectivity over $\alpha IIb\beta 3$, by using cyclic RGD and incorporating one D-amino acid. The latter modification, based on a process called: “spatial screening”^{25–28}, had a drastic impact on the backbone conformation, that changed the selectivity and affinity pattern of the cyclic peptides. These studies revealed that ligands presenting the RGD motif in an extended conformation with distances of 0.7–0.9 nm between the positively-charged arginine residue and the carboxyl group of aspartate, bind preferentially to $\alpha IIb\beta 3$ ²⁹. In contrast, if the binding motif is more bent or kinked (as is the situation with the cyclic pentapeptide *c*(RGDf(NMe)Val) (= *Cilengitide*)^{30,31}, ligands tend to bind preferably to other subtypes, such as $\alpha v\beta 3$ and $\alpha 5\beta 1$. The crystal structures of integrin antagonists docked into the $\alpha v\beta 3$ or $\alpha IIb\beta 3$ receptor pocket^{32–34}, explained and corroborated this phenomenon, in retrospect (see Fig. 1 and discussion below).

Another crucial aspect of achieving selectivity for $\alpha IIb\beta 3$, is the substitution of the guanidine group in the ligand by an amine. In all RGD-binding subtypes except for $\alpha IIb\beta 3$, the guanidine group is bound via bifurcated salt bridges to the α -subunit (see Fig. 1), and an amine is not recognized. The binding mode in $\alpha IIb\beta 3$ is slightly different and thus, Arg-to-Lys substitution leads to a strong enhancement of the selectivity for $\alpha IIb\beta 3$. Nature has developed this alteration, resulting in obtaining selective $\alpha IIb\beta 3$ -specific ligands, avoiding crosstalk with other integrin subtypes.

Due to the similarity of the RGD binding regions in most integrins, it is not straightforward to achieve high selectivity and, at the same time, high affinity of small synthetic ligands, for distinct subtypes. In fact, most of the ligands described so far as subtype-selective have residual, yet significant affinity to other integrins as well. Recently, we, as well as others, were able to develop ligands with sufficient activity and selectivity to effectively discriminate between two closely related integrin subtypes, such as $\alpha v\beta 3$ and $\alpha 5\beta 1$ ^{35–37} or $\alpha v\beta 6$ ³⁸. Their functionalization enabled the selective imaging of $\alpha v\beta 3$ - or $\alpha 5\beta 1$ -expressing tumors in a mouse model, and the differential

	$\alpha v\beta 3$ [nM]	$\alpha v\beta 5$ [nM]	$\alpha v\beta 6$ [nM]	$\alpha v\beta 8$ [nM]	$\alpha 5\beta 1$ [nM]	$\alpha IIb\beta 3$ [nM]	Ref
Echistatin	0.46 ± 0.14	1.4 ± 0.2	13.7 ± 0.3	12.8 ± 2.5	0.57 ± 0.19	0.90 ± 0.24	58,59
RGD	89 ± 12	440 ± 65	> 10000	> 10000	335 ± 40	> 10000	
RGDS	45 ± 5	433 ± 34	> 10000	> 10000	181 ± 23	> 10000	
GRGD	55 ± 7	580 ± 23	> 10000	> 10000	137 ± 14	> 10000	
GRGDS	28 ± 3	260 ± 42	1480 ± 162	> 10000	77 ± 8	> 10000	
GRGDSP	13.7 ± 0.3	167 ± 39	693 ± 40	> 10000	51 ± 8	> 10000	
GRGDSPK	12.2 ± 0.1	201 ± 32	1030 ± 242	> 10000	66 ± 6	> 10000	
GRGDNP	45 ± 12	506 ± 120	> 10000	> 10000	34 ± 3	> 10000	63
GRGDTP	28 ± 5	423 ± 65	> 10000	> 10000	84 ± 12	> 10000	64
c(RGDfV)	1.54 ± 0.12	250 ± 15	49 ± 5	> 10000	200 ± 41	> 10000	26,25
Cilengitide	0.61 ± 0.06	8.4 ± 2.1	2050 ± 640	2350 ± 438	14.9 ± 3.1	5400 ± 814	30,31
c(RGDfK)	2.25 ± 0.34	340 ± 24	55 ± 9	5200 ± 670	141 ± 15	> 10000	77
c(RGDyK)	3.8 ± 0.42	503 ± 55	86 ± 7	> 10000	236 ± 45	> 10000	80
c(RGDfC)	6.3 ± 0.5	433 ± 23	121 ± 10	> 10000	215 ± 55	> 10000	81
sn243	0.65 ± 0.05	199 ± 21	>10000	>10000	108 ± 27.5	>10000	37
RGD-4C	8.3 ± 2.1	46 ± 11	380 ± 44	> 10000	244 ± 37	> 10000	83
RGD10 (RGD-2C)	10.3 ± 2.9	102 ± 11	278 ± 34	> 10000	133 ± 52	> 10000	84
NC100717	1.1 ± 0.1	16.7 ± 2.1	> 10000	> 10000	820 ± 156	> 10000	85
c(phgisoDGRk)	> 10000	> 10000	18 ± 2.5	77 ± 6	9.43 ± 1.33	> 10000	52
44b	> 10000	> 10000	433 ± 101	37 ± 3	2.3 ± 0.02	> 10000	91
ATN161	> 10000	> 10000	3133 ± 591	> 10000	4.2 ± 0.5	> 10000	90
JSM6427	> 10000	> 10000	23 ± 3.4	8.2 ± 0.52	2.5 ± 0.4	> 10000	36
RTDLDSLRT	6233 ± 540	> 10000	29.5 ± 4.5	320 ± 25	> 10000	> 10000	93
A20FMDV2	> 10000	> 10000	0.93 ± 0.07	45 ± 4.1	> 10000	> 10000	94
Mol11*	13.2 ± 0.5	530 ± 49	1.32 ± 0.04	18.5 ± 4.3	3020 ± 410	> 10000	49
c(FRGDLAFp(NMe)K)	1200 ± 240	>10000	0.28 ± 0.019	24 ± 3.1	73 ± 6	>10000	38
Eptifibatide	> 10000	> 10000	> 10000	> 10000	> 10000	2.44 ± 0.45	95
Tirofiban	> 10000	> 10000	> 10000	> 10000	> 10000	1.3 ± 0.04	96
GR144053	> 10000	> 10000	> 10000	> 10000	> 10000	18 ± 2.2	97

* (S-Enantiomer)

Table 1. IC₅₀-values for the integrin ligands investigated for the subtypes $\alpha v\beta 3$, $\alpha v\beta 5$, $\alpha v\beta 6$, $\alpha v\beta 8$, $\alpha 5\beta 1$, and $\alpha IIb\beta 3$. Specificity or subtype with the lowest IC₅₀-value are highlighted. All values were referenced as given in the description of the assay and in the SI. *(S-Enantiomer).

	$\alpha v\beta 3$	$\alpha v\beta 5$	$\alpha v\beta 6$	$\alpha v\beta 8$	$\alpha 5\beta 1$	$\alpha IIb\beta 3$	Ref.
	[nM]	[nM]	[nM]	[nM]	[nM]	[nM]	
F-Galacto-c(RGDfK)	8.2 ± 0.46	310 ± 39	840 ± 192	> 10000	41 ± 2.9	> 10000	100
(Ga)NOPO*-c(RGDfK)	1.1 ± 0.09	299 ± 36	255 ± 64	> 10000	25 ± 2.1	> 10000	101
c(RGDfK)-Peg-MPA	15 ± 1.8	390 ± 53	422 ± 44	> 10000	201 ± 31	> 10000	52
Flucilatide	2.3 ± 0.3	36 ± 5	> 10000	> 10000	1170 ± 230	> 10000	86
c(phgisoDGRk)-Peg-MPA	> 10000	> 10000	52 ± 4.8	> 10000	31 ± 3.4	> 10000	52

Table 2. IC₅₀-values for the functionalized integrin ligands investigated for the subtypes $\alpha v\beta 3$, $\alpha v\beta 5$, $\alpha v\beta 6$, $\alpha v\beta 8$, $\alpha 5\beta 1$ and $\alpha IIb\beta 3$. Specificity or subtypes with the best IC₅₀-values are highlighted, respectively. All values were referenced as given in the description of the assay and in the SI. NOPO 1,4,7-triazacyclononane-1,4-bis[methylene(hydroxymethyl)phosphinic acid]-7-[methylene(2-carboxyethyl)phosphinic acid. *21-amino-4,7,10,13,16,19-hexaoxaheneicosanoic acid.

cell binding on different surfaces^{39,40}. These molecules were developed by ligand oriented molecular design and later refined on the basis of X-ray structures of the integrins $\alpha v\beta 3$ and $\alpha IIb\beta 3$ ^{32,33,41} and the homology model for $\alpha 5\beta 1$ ^{42–44}. It is interesting to note that the later published crystal structure of $\alpha 5\beta 1$ structurally confirmed the selectivity described for these ligands⁴⁵.

Both, the $\alpha v\beta 3$ - and the $\alpha 5\beta 1$ -selective ligands bind the integrins via the kinked RGD motif, but differences are found in the binding mode of the arginine side chain. As illustrated in Fig. 1, which depicts a linear RGD-ligand in the binding pocket, the guanidine group of arginine is binding in a side-on manner to the Asp218 of the α -subunit of $\alpha v\beta 3$, forming a bidentate salt bridge. In addition to this side-on interaction (Asp227 in $\alpha 5$), an end-on interaction of guanidine and Gln221 can be observed in the crystal structure of $\alpha 5\beta 1$ ⁴⁵. Keeping this difference in mind, the selectivity of the ligands can be explained as follows: the amino pyridine in **sn243** interacts side-on with the αv -pocket but does not allow an end-on binding due to sterical hindrance, thus reducing strongly the $\alpha 5\beta 1$ affinity. On the other hand, **44b** has a full guanidine function allowing side-on and end-on interactions. Recently, we described a way how this small difference between the αv - and the $\alpha 5$ -binding pocket can be utilized to design selective peptidic integrin ligands. By alkylation of the N_ω of the guanidine group of arginine, the $\alpha 5$ -specific *end-on* interaction is blocked, leading to a shift in selectivity for αv -integrins⁴⁶.

Apart from targeting integrins $\alpha v\beta 3$, $\alpha 5\beta 1$, or $\alpha IIb\beta 3$, other clinically relevant integrin subtypes have been explored¹⁶. For instance, several linear peptides, containing a helical DXLLX motif, were shown to selectively bind $\alpha v\beta 6$ and $\alpha v\beta 8$, and display low affinity towards all other subtypes. The biological role of $\alpha v\beta 6$ and $\alpha v\beta 8$ is quite similar, as they are both participating in the activation of transforming growth factor- β (TGF- β) by interacting with the same endogenous ligands TGF- $\beta 1$ and TGF- $\beta 3$ ⁴⁷. Finally, $\alpha v\beta 3$ and $\alpha v\beta 5$ share very similar biological roles (stimulate angiogenesis), but they perform this task via different mechanisms⁴⁸. Nevertheless, their close structural similarity hampers the development of selective ligands to these integrins^{49,50}.

The aims of this work. Since the discovery and first application of integrin-binding RGD peptides in the 1980s, and based on their great impact in medicine, biology, and biophysical sciences, the design and use of synthetic integrin ligands attracts much attention. Most of the current research is focused on the discovery of new integrin-selective ligands and their use for drug delivery, diagnosis, and tumor imaging, which are crucial for developing effective personalized medical platforms.

However, unequivocally ascribing a specific biological role to one integrin receptor remains problematic. Even when high binding affinity towards one distinct integrin subtype is achieved, it often remains unclear whether the observed biological effect is not based on a residual effect on another subtype. This may be attributed to the fact that most studies so far have only focused on the selectivity between a reduced subset of integrins, e.g. $\alpha v\beta 3$ vs. $\alpha IIb\beta 3$, or $\alpha v\beta 3$ vs. $\alpha 5\beta 1$, but have totally neglected the influence of other closely related integrins of the RGD-binding family. This is particularly problematic as integrin expression strongly depends on cell and tissue type, crosstalk within distinct integrin subtypes, time point of study, and biological environment (e.g. tissue type). Last but not least, the activities reported for integrin ligands are usually evaluated using different experimental protocols and are, thus, highly variable.

Consequently, no reliable comprehensive comparison of the IC₅₀-values of biologically prominent integrin ligands has been made, so far. Newly designed integrin ligands have seldom been evaluated for their selectivity against a full panel of RGD-binding integrin subtypes, mainly because there were no reliable testing systems established.




Figure 2. Schematic illustration of the enzyme-linked immunosorbent assay (ELISA). (A) 1. Each well (96-well plate) is coated with an ECM protein (e.g. vitronectin for $\alpha v\beta 3$). 2. Uncoated surface is blocked by bovine serum albumin (BSA). 3. ECM protein competes with the tested ligand for binding to the soluble integrin (e.g. $\alpha v\beta 3$). 4. Integrin bound to ECM protein is detected by an integrin-specific primary antibody. 5. Secondary antibody, conjugated with a peroxidase (POD), detects bound primary antibody. 6. Peroxidase converts a colorless substrate into a colored substrate (TMB, 3,3',5,5'-tetramethylbenzidine). (B) The ligand inhibits binding of the coated ECM protein to the integrin. Consequently, steps 3–6 are blocked and no color signal can be detected.

In this work, we have evaluated a large number of well-known and widely used integrin-targeting molecules using the same standardized competitive ELISA-based test system, by measuring the inhibition (i.e. IC_{50} values) of integrin binding to immobilized natural ECM ligands. In order to facilitate a direct comparison, we show here (Tables 1 and 2) the affinity values determined with our test system, which always contained reference compounds to standardize the biological data. For some ligands, IC_{50} values were already reported in the literature and the inhibitory activities might slightly deviate from our present data. However, we consider that a direct comparison under identical conditions is very important and thus only represent the data determined during this work. This study includes RGD-based linear and cyclic peptides, peptide-mimetics as well as commonly used reference compounds. Furthermore, in this study we demonstrate, with carefully selected molecules, how functionalization of integrin ligands (e.g. with chelators, anchoring groups) can affect their binding affinity and selectivity. The investigated integrin subtypes studied here include: $\alpha v\beta 3$ and $\alpha v\beta 5$ (both binding to vitronectin), $\alpha v\beta 6$ and $\alpha v\beta 8$ (binding to LAP), $\alpha 5\beta 1$ (binding to fibronectin) and $\alpha IIb\beta 3$ (binding to fibrinogen), which are all RGD-binding (the only missing RGD-binding integrins are $\alpha v\beta 1$ and $\alpha 8\beta 1$, which could not be screened in our test system) and have relevant clinical implications. Since none of the presented ligands have previously been evaluated against such an exhaustive panel of integrin subtypes, the results of this study will provide unprecedented insights into the binding and selectivity profiles of synthetic integrin ligands, thus being of great value for the further development of integrin inhibitors for medical applications. In general, these binding activities correlate very strongly with the inhibition of signal transduction and with the binding affinity of the biochemically highly complex focal adhesions to ECM proteins.

An overview of the main approaches for testing integrin subtype-specific ligands. For the development and optimization of biologically active integrin ligands it is of utmost importance to use a reliable and reproducible test system, which yields values for biological activity with low statistical variance and high precision. A careful revision of previously published integrin-binding affinity data for well-known integrin ligands seems to indicate clear differences between the methods used. In general, cell-based methods are strongly dependent on the experimental condition of the study. Thus, the affinity data obtained for the same compound and the same integrin may greatly vary in different cell-based studies. In contrast, non-cellular systems, which are based on the use of isolated integrin receptors, tend to exhibit better biochemical precision and reproducibility. The major drawback of these methods, however, is the fact that they represent a simplified and artificial system, which does not fully mimic the intricate nature of integrin-ligand interactions and the subsequent response of the adhesome-associated signaling. Thus, an efficient combination of both systems is highly recommended for an optimal and efficient development of integrin-targeting drugs. In the following section, several cellular and non-cellular tests are briefly described.

In vitro cellular tests have been widely used to obtain integrin affinity data. A well-established and commonly used method is based on the concentration-dependent inhibition of cell attachment to a surface that is usually coated with the native cell adhesive proteins⁵. Prior to the test, cells are plated on a surface and afterwards incubated with the soluble compound in different concentrations. Alternatively, cells are incubated in the presence of the integrin ligand, which blocks their attachment to the surfaces. For the evaluation, the attached cells are viewed

by transmitted light microscopy, by fluorescence microscopy (in cases when the cells are tagged), or upon use of other functional imaging approaches. Such tests can be performed with a variety of cell types (e.g. NRK-epithelial cells, MG-63, MDA-MB-435⁵¹ or REF52⁵²), as well as with platelets isolated from platelet-rich plasma. Another popular cell-based technique is the calculation of integrin binding affinities based on ligand binding assays⁵³. Suspended or adherent cells are incubated with increasing concentrations of an integrin ligand, and afterwards with a radiolabeled ligand that also shows integrin-binding affinity, such as ¹²⁵I-Echistatin or ¹²⁵I-c(RGDyK). The radioligand is therefore competing with the compound for binding to the integrin receptors on the cell surface and serves as an internal standard reference for the binding affinity. As described for the cell adhesion assay, a great choice of integrin expressing tumor cell lines as well as epithelial cells are available, such as 293-b $\beta 3$ ⁵⁴ or U87MG glioblastoma⁵⁵.

Cell-based tests hold great potential to evaluate not only ligand binding but also its capacity to trigger biological responses relevant for the physiological context. This holds true at least for cases in which the “reporter” cell type is physiologically relevant. It is noteworthy that cellular tests possess some serious intrinsic limitations that are of particular importance during drug development. The major drawback is the limited control over homogeneity in the levels of integrin expression present in the different cell lines used, or even in individual cells in the tested population. Typically, there is one highly overexpressed integrin subtype presented on the surface, but there may also be other minor populated integrin subtypes to which the tested compounds may bind. It is even more problematic that these subtype expression levels may change over time. In addition, the total surface receptor density can strongly vary depending on specific conditions (number of passages in culture, presence of other integrins, cell culture conditions, state of cell cycle etc.). For example, a phenomenon known as “integrin crosstalk” has been proven for $\alpha v\beta 3$ and $\alpha 5\beta 1$. Specifically, $\alpha 5\beta 1$ integrin was shown to modulate (up or down) the expression of another subtype and thus significantly alters the expression pattern⁵⁶. Consequently, the comparison of affinity data measured for different cell lines is highly challenging.

Tests carried out in cell-free systems, use isolated extracellular domains of integrins in conjunction with ECM proteins, either extracted from human tissue or produced by recombinant methods. Most of these tests are based on competitive solid phase binding assays, in which one component is bound to the multi-well plate and in a subsequent step, soluble ligands are added, testing their capacity to block the binding to that component. Mainly two procedures are described in the literature, differing in the molecule used to coat the surfaces: the isolated integrin extracellular domains or the ECM protein. In the first case, the integrin is coated on the surface, followed by an incubation with a mixture of the native ECM protein and increasing concentrations of the ligand of interest⁴⁹. In an alternative test system, the natural ECM protein (vitronectin for $\alpha v\beta 3$ and $\alpha v\beta 5$, LAP (TGF β) for $\alpha v\beta 6$ and $\alpha v\beta 8$, fibronectin for $\alpha 5\beta 1$ and fibrinogen for $\alpha IIb\beta 3$) is immobilized onto the surface, and the soluble integrin, together with a serial dilution of the inhibitory ligand, is added afterwards⁵⁷. The read-out in both procedures is usually done in an ELISA-like manner by using conjugated antibodies recognizing the integrin head groups. A detailed schematic illustration of the different steps of the integrin binding assay is presented in Fig. 2. In comparison to many other test systems, this system allows the accurate (SD~10%) and reproducible determination of IC₅₀ values for almost all RGD-binding integrin subtypes. For a detailed description of the reference to the SI. As the quality of the integrins strongly depend on the batch and providers a reference compound always have to be used for each test plate as internal standard (we used: **Cilengitide**, c(RGDf(NMe)V) ($\alpha v\beta 3$ –0.54 nM, $\alpha v\beta 5$ –8 nM, $\alpha 5\beta 1$ –15.4 nM), linear peptide **RTDLSLRT** ($\alpha v\beta 6$ –33 nM; $\alpha v\beta 8$ –100 nM) and **tirofiban** ($\alpha IIb\beta 3$ –1.2 nM).

Preliminary studies in our laboratories comparing the two methods (surface-bound integrin vs. soluble integrin) revealed significant differences in the antagonistic activity of control ligands in regards to the integrin subtype used. Whereas very similar IC₅₀ values were found regardless of the method used for integrins $\alpha v\beta 3$ or $\alpha v\beta 5$, the activity towards $\alpha 5\beta 1$ seemed to be highly dependent on the experimental protocol. The drug **Cilengitide** exhibited very high affinity (in the low nanomolar range) towards soluble $\alpha 5\beta 1$ when fibronectin (i.e. the natural ECM ligand) was immobilized on surfaces. However, coating of the integrin and subsequent incubation of **Cilengitide** with fibronectin generally resulted in low antagonistic activities and poor reproducibility within assays (unpublished data). This was already observed in our stem peptide **c(RGDfv)**²⁶, and may be attributed to the possible denaturation of $\alpha 5\beta 1$ integrin.

Results and Discussion

The gold standard integrin inhibitor, Echistatin. The disintegrin **Echistatin** was first isolated in 1988 from snake venom as an effective inhibitor of platelet-fibrinogen interaction, as well as of platelet aggregation⁵⁸. This small folded protein contains an RGD-sequence in a well-exposed loop which was described to bind to $\alpha IIb\beta 3$, $\alpha v\beta 3$, $\alpha v\beta 5$, and $\alpha 5\beta 1$ with very high affinity⁵⁹. Since the Tyr-31 residue of **Echistatin** can be labeled with ¹²⁵I using a standard procedure has turned this compound into a commonly used positive control for many competitive cellular integrin binding assays^{60,61}. We therefore included **Echistatin** in our study to determine its selectivity profile and to compare its binding activities to those previously obtained from cellular assays. **Echistatin** showed a very broad affinity pattern. It binds to the whole panel of investigated integrins with IC₅₀-values in the low nano-molar range (Table 1). As already reported, it shows particularly low IC₅₀-values for $\alpha v\beta 3$ (0.46 nM), $\alpha 5\beta 1$ (0.57 nM), and $\alpha IIb\beta 3$ (0.9 nM). Interestingly, **Echistatin** exhibited the lowest IC₅₀-values for these integrins compared to all other compounds investigated within this study. Thus, it also represents an ideal candidate to be included as a positive control in cell-free integrin binding tests.

Linear RGD integrin inhibitory peptides. The RGD-sequence was originally discovered as the minimal binding epitope of fibronectin and has extensively been investigated over the last decades. Moreover, it has been shown that the presence and chemical nature of flanking residues have a strong influence on its activity⁵. Thus, early studies with the RGD-motif were conducted with linear tri- to heptapeptides, based on the sequence found

in fibronectin. In our study, the following linear peptides were included: **RGD**, **RGDS**, **GRGD**, **GRGDS**, **GRGDSP**, and **GRGDSPK**. In original reports, these peptides were described to bind to $\alpha v\beta 3$ and $\alpha v\beta 5$, but also showed relatively good IC_{50} -values for the integrin subtypes $\alpha 5\beta 1$ and $\alpha v\beta 6$, as well as low affinity for $\alpha IIb\beta 3$ ⁶². Apart from the compounds mentioned above, **GRGDNP**⁶³ and **GRGDTP**⁶⁴ peptides were also included in our test system, as they are frequently used in biological studies. Especially, **GRGDNP** has been described to prefer binding to $\alpha 5\beta 1$. In our evaluation, all linear peptides showed the lowest IC_{50} -values for the integrin subtype $\alpha v\beta 3$ (12–89 nM), with IC_{50} -values for $\alpha v\beta 5$ ranging from 167 to 580 nM and for $\alpha 5\beta 1$ from 34 to 335 nM. These peptides generally displayed high IC_{50} -values towards $\alpha v\beta 6$ and $\alpha v\beta 8$. More surprisingly, none of the linear peptides exhibited an IC_{50} -value below 10 μ M on $\alpha IIb\beta 3$. These results demonstrate that the linear RGD peptides are active on integrins $\alpha v\beta 3$, $\alpha v\beta 5$, and $\alpha 5\beta 1$, and selective against $\alpha v\beta 6$, $\alpha v\beta 8$ and $\alpha IIb\beta 3$. As presented in Table 1, the residues flanking the RGD-motif essentially contribute to the binding affinity for $\alpha v\beta 3$ (and to a lower extent for $\alpha 5\beta 1$ and $\alpha v\beta 5$). In particular, the IC_{50} -value to $\alpha v\beta 3$ increases 7-fold from the linear tripeptide fragment **RGD** (89 nM) to the heptapeptide **GRGDSPK** (12.2 nM).

Cyclic RGD peptides. A major disadvantage of linear peptides is their low stability regarding enzymatic degradation, limiting their applicability for *in vivo* studies⁶⁵. This can be significantly improved by cyclization and incorporation of a D-amino acid residue, as illustrated by cyclic pentapeptides of the formula $c(RGDxX)$ and cyclic hexapeptides⁶⁶. Moreover, reduction of the conformational space by cyclization can improve the biological potency of linear peptides when the bioactive conformation is matched⁶⁷. One of the first cyclic compounds that was developed and used in cellular studies was **c(RGDfV)** which showed outstanding affinity for $\alpha v\beta 3$, while retaining total selectivity against $\alpha IIb\beta 3$. This core structure was later modified to develop a series of new ligands with improved activity and selectivity profiles^{68,69}. Extensive Structure-Activity Relationship (SAR) studies on the model sequence $c(RGDxX)$ showed, that the presence of an aromatic amino acid in the D-configuration (i.e. D-Phe, D-Tyr, D-Trp) at the position 4 (residue x) was essential for the $\alpha v\beta 3$ -binding affinity, whereas the amino acid at position 5 (residue X) had little effect on the biological activity^{68,69}. Based on the stem peptide $c(RGDfV)$, **Cilengitide**, $c(RGDf(NMe)V)$, the most active cyclic pentapeptide described to date, was developed via a systematic N-methylation scan. **Cilengitide** has a half-life in man of about four hours and is not metabolized systemically⁷⁰. It became a drug candidate in phase II and III clinical studies for the treatment of different tumors^{71–74}, however failed in phase III as drug against glioblastoma. Despite its extraordinarily low IC_{50} -value for $\alpha v\beta 3$ and $\alpha v\beta 5$, the higher, but still significant value for $\alpha 5\beta 1$ subtype is often neglected⁷⁵. In this regard, our study clearly shows that this compound has also a remarkably low IC_{50} -value for $\alpha 5\beta 1$ (14.9 nM). Noteworthy, the IC_{50} for $\alpha v\beta 3$ (0.61 nM) and $\alpha v\beta 5$ (8.4 nM) were the highest obtained among all synthetic peptides developed and studied. As previously indicated, the valine residue can be substituted by almost any other amino acid⁶⁶. Hence, for biophysical or medical applications where a functionalization or ligation of integrin ligands is needed, the derivative **c(RGDfK)**⁷⁶ is often used. Lys has been found to be a good anchoring point for the attachment of functional units not only because it does not affect the binding affinity of the stem peptide significantly, but also because it easily allows the linkage of other chemical groups via the free amine. A pilot study by us used acrylate-functionalized derivatives of **c(RGDfK)** to mediate the adhesion of osteoblasts on a polymethylmetacrylate (PMMA) surface⁷⁷. Since that time, **c(RGDfK)** and also **c(RGDfE)** were functionalized for a large number of biological applications^{78,79}. Other cyclic penta-peptides used for functionalization are **c(RGDyK)**⁸⁰ as well as **c(RGDfC)**⁸¹, are both included in our study. Just like the linear peptides, all of the cyclic pentapeptides of the type $c(RGDxX)$ tested showed moderate to low IC_{50} -values for $\alpha v\beta 3$, $\alpha v\beta 5$, and $\alpha 5\beta 1$, and no binding to $\alpha IIb\beta 3$, which is of major importance for *in vivo* applications. Noteworthy, all the cyclic peptides displayed lower $\alpha v\beta 3$ IC_{50} -values (i.e. in the range of 1.5 to 6 nM) compared to the linear derivatives, and followed the order **c(RGDfV)** < **c(RGDfK)** < **c(RGDyK)** < **c(RGDfC)**. Therefore, cyclic RGD-peptides should be the preferred choice when high $\alpha v\beta 3$ -binding activities are required. The IC_{50} values for $\alpha v\beta 5$ and $\alpha 5\beta 1$ varied from 250 to 503 nM and from 141 to 236 nM, respectively. Interestingly, all the cyclic compounds showed relatively low IC_{50} -values for $\alpha v\beta 6$ (49–75 nM), which has not been discussed in any of the references so far.

Ruoslahti *et al.* discovered the RGD-containing double cysteine-bridged (1–4, 2–3) peptide **RGD-4C**⁸² (ACDCRGDCFCG) by phage display and reported a low IC_{50} -value towards the subtypes $\alpha v\beta 3$ and $\alpha v\beta 5$, and specificity over $\alpha 5\beta 1$. This peptide represents one of the most commonly used molecules in cellular tests and in *in vivo* studies and has been conjugated to target $\alpha v\beta 3$ -overexpressing cells⁸³. To reduce the synthetic complexity that arises from two disulfide bridges, Hölig *et al.* developed the single cysteine-bridged peptide **RGD10** (GARYCRGDCFDGR)⁸⁴, which has the same IC_{50} value and selectivity properties as the original **RGD-4C**, and has been functionalized for different applications as well, (e.g. for surfaces coating or targeting liposomes). In our studies, the **RGD-4C** peptide exhibited an IC_{50} -value for $\alpha v\beta 3$ of 8.3 nM, which is comparable to that observed for the best linear RGD-sequences but considerably lower than that of cyclic RGD-containing penta-peptides. Furthermore, it also shows a good value for $\alpha v\beta 5$ (46 nM), a high IC_{50} -value for $\alpha v\beta 6$ and $\alpha 5\beta 1$, and no affinity for $\alpha v\beta 8$ and the platelet integrin $\alpha IIb\beta 3$. As reported in other studies, **RGD-10** exhibits a similar pattern of bioactivity, though with a trend towards increased $\alpha v\beta 3/\alpha v\beta 5$ selectivity: the IC_{50} for $\alpha v\beta 3$ remains almost the same, whereas the $\alpha v\beta 5$ affinity drops to 102 nM. Based on the **RGD-4C** peptide, Indrevoll *et al.* developed a PEGylated bicyclic, mono cysteine-bridged peptide with the sequence KCRGDCCFC (**NC100717**)⁸⁵ targeting the $\alpha v\beta 3$ and $\alpha v\beta 5$ integrin subtype. This scaffold is the targeting unit of functionalized compounds (chelators and dyes), e.g. the ¹⁸F-labeled compound ¹⁸F-**AH11858** (Fluciclatide⁸⁶, GE), described in detail in the section of functionalized molecules. **NC100717** showed a low nanomolar IC_{50} -value for $\alpha v\beta 3$ (1.1 nM) and $\alpha v\beta 5$ (41 nM) in our test system. Nonetheless, for application of disulfide-bridged cyclic peptides it may be of interest to consider the stability of disulfide bridges *in vivo*⁸⁷. Finally, another integrin binding motif in fibronectin is the inverse sequence **isoDGR** which is based on the NGR motif after *in situ* rearranging from asparagine to *iso* aspartate^{88,89}. The integrin subtype selectivity strongly varies depending on the flanking residues of the sequence. Recently, the

compound **c(phgisoDGRk)**⁵⁰, which is bi-selective for $\alpha v\beta 6$ and $\alpha 5\beta 1$, was identified and used for cellular studies. In our test system, it could be shown here that the compound moreover binds to $\alpha v\beta 8$ as well.

Peptidomimetics and other ligands. The non-RGD linear pentapeptide Ac-PHSCN-NH₂ was derived from the synergy domain of fibronectin and is clinically developed under the trade name **ATN161**⁹⁰ for the treatment of several solid tumors as it is highly active for the $\alpha 5\beta 1$ subtype, with some affinity for $\alpha v\beta 3$ and $\alpha v\beta 5$ ¹⁶. Interestingly, **ATN161** showed a clear selectivity for $\alpha 5\beta 1$ (4.2 nM) in our testing system, being essentially inactive for all other integrins investigated.

The non-peptidic compound **JSM6427**³⁶ was designed by Stragies *et al.* and later developed in clinical phase for the treatment of age-related macular degeneration as it strongly inhibits neovascularization in the eye. It is described to be a relatively selective $\alpha 5\beta 1$ antagonist, although values for $\alpha v\beta 6$ and $\alpha v\beta 8$ were not published. Indeed, we found **JSM6427** to be tri-selective for $\alpha 5\beta 1$ (2.5 nM), $\alpha v\beta 6$ (23 nM), and $\alpha v\beta 8$ (8.2 nM).

Recently, we reported the synthesis and binding affinity of the highly active $\alpha v\beta 3$ -selective **sn243**³⁷ and the $\alpha 5\beta 1$ -selective **44b**⁹¹ peptidomimetic ligands. In a proof-of-concept study, these compounds were functionalized and used for molecular imaging⁹² as well as for biophysical studies^{39,40}, showing their potential to discriminate the two integrin subtypes $\alpha v\beta 3$ and $\alpha 5\beta 1$ both, *in vitro* and *in vivo*. Here, we also included them to evaluate their full pattern of integrin selectivity, and found, besides the expected high activities for the corresponding subtype (**sn243**: 0.65 nM $\alpha v\beta 3$; **44b**: 2.3 nM $\alpha 5\beta 1$), a low nanomolar IC₅₀-value for $\alpha v\beta 8$ for **44b** (37 nM).

Integrin $\alpha v\beta 6$ -binding ligands. The α -helical binding motif DLXXL, an $\alpha v\beta 6$ subtype-specific binding motif, was initially discovered by phage display and later shown to be also present in the natural $\alpha v\beta 6$ ligand latency associated peptide (LAP). Two compounds containing this motif are included in this study as they have extensively been used for addressing selectively $\alpha v\beta 6$ -expressing cells *in vivo*, e.g. as targeting unit for molecular imaging. The RTD containing 9-mer peptide **RTDLSLRT**⁹³ as well as the 20-mer peptide **A20FMDV2**⁹⁴, which is derived from a foot and mouth disease virus peptide (sequence: NAVPNLRGDLQVLAQKVART), were proven to be subtype-selective in our study and exhibited an IC₅₀-value of 29.5 and 0.93 nM for $\alpha v\beta 6$, respectively. The peptidomimetic compound **Mol11**⁴⁹, which was described as the first $\alpha v\beta 6$ selective small molecule ligand, was resynthesized for this study as an enantiomerically pure (*S*-enantiomer) compound and indeed showed a very low IC₅₀-value for $\alpha v\beta 6$ (1.3 nM), but also good values in the lower nanomolar range for $\alpha v\beta 3$ (13.2 nM), and $\alpha v\beta 8$ (18.5 nM). Recently, we were able to develop the cyclic peptide **c(FRGDLAfp(NMe)K)**³⁸, which mimics the binding epitope of the helical DLXXL-motif. The IC₅₀ of this peptide was determined to be 0.28 nM for $\alpha v\beta 6$, the highest affinity among the compounds investigated.

Integrin $\alpha IIb\beta 3$ -binding ligands. The $\alpha IIb\beta 3$ integrin receptor, also known as glycoprotein receptor (GP)-IIb/IIIa, is expressed uniquely on the surface of platelets and megakaryocytes, a type of platelet-producing cells in the bone marrow. By binding to its natural ligand fibrinogen, $\alpha IIb\beta 3$ is involved in primary hemostasis during platelet formation. Thus, application of $\alpha IIb\beta 3$ ligands was earlier explored as a clinical approach for anti-thrombotic therapy¹⁵. Today, there are two FDA-approved drugs targeting selectively the $\alpha IIb\beta 3$ receptor, Intrifiban (**Eptifibatide**)⁹⁵ and **Tirofiban** (Aggrastat)⁹⁶, both clinically used for patients with acute coronary syndromes undergoing percutaneous coronary intervention. **Eptifibatide** is a cysteine-bridged cyclic RGD-containing hexapeptide. It was first described in 1993 as a potent subtype-selective integrin antagonist and is, as well as the small molecule $\alpha IIb\beta 3$ inhibitor **Tirofiban**, used both clinically and preclinically. Another $\alpha IIb\beta 3$ selective compound included in this comparison of integrin ligands is **GR144053**⁹⁷. It is described as an orally available, highly potent subtype-selective fibrinogen inhibitor and is used in many preclinical studies. In our test system, these three compounds have been confirmed to be selective $\alpha IIb\beta 3$ inhibitors. The lowest $\alpha IIb\beta 3$ IC₅₀-value was determined for **Tirofiban** (1.3 nM), followed by **Eptifibatide** (2.8 nM) and **GR144053** (18 nM).

Functionalized compounds. Many of the integrin ligands that are used for biophysical or medical experiments require a functional unit (e.g. for a strong covalent binding to the surface) or a chelator for molecular imaging. For that reason, the bioactive moiety is linked to this functionality via a spacer that separates the two entities of the molecule. Ideally, by using the right anchoring point in the molecule, the loss of activity upon functionalization is low. Nevertheless, the size, lipophilicity, and other parameters like the rigidity of the functional as well as the spacing unit can influence the binding of the bioactive moiety to its target^{98,99}. To estimate the influence on the IC₅₀-values after modification of the ligand, five compounds were chosen as examples (Table 2). Among three of them, **c(RGDfK)**, which is functionalized via its lysine side chain, represents the bioactive targeting unit. The IC₅₀-value of the unmodified ligand was determined to be 2.3 nM for the $\alpha v\beta 3$ integrin subtype (Table 1). After modification to **F-Galacto-c(RGDfK)**¹⁰⁰ (for molecular imaging) and **c(RGDfK)-Peg-MPA** (MPA = mercapto propionic acid), the IC₅₀ moderately decreased to 8 and 15 nM, respectively. Exactly the opposite, namely a better $\alpha v\beta 3$ IC₅₀ was observed for the **(Ga)NOPO-c(RGDfK)** (1.1 nM)¹⁰¹. This phenomenon could already be observed for previously published compounds and can be explained, *inter alia*, by charge effects and/or altered van-der-Waals interactions. For example, large substituents like chelators possess a high surface area and can randomly interact via unspecific van-der-Waals interactions with parts of the protein. This weak interaction decreases the *k_{off}*-rate and thus can lead to IC₅₀-values compared to the original targeting peptide alone. Concerning the selectivity profile of the modified compounds, no changes are observable. This is also found for the $\alpha v\beta 6/\alpha 5\beta 1$ bi-selective peptide **c(phgisoDGRk)**, where the selectivity is not affected but the IC₅₀-value for the two integrins doubles (2-fold) after functionalization to **c(phgisoDGRk)-Peg-MPA**⁵². **Fluciclatide**, an imaging agent developed by GE Healthcare, consists of **NC100717** as targeting unit⁸⁴. For this example, the IC₅₀-value for $\alpha v\beta 3$ decreased 3-fold and no change in selectivity was observable. To sum up, the functionalization of a bioactive molecule can alter its integrin binding affinity. This means that in principle, every functionalized compound for

both *in vitro* and *in vivo* applications should be tested individually to obtain comparable results. It is important to mention here that e.g. the introduction of a PEG spacer does not guarantee better ligands properties (solubility, affinity). Peg is not always extended in aqueous solution and thus the distance between the biomolecule and the functional unit is not defined⁹⁹. Changes in affinity induced by a spacer and a functional unit are hard to predict. Additionally, functionalization of bioactive compounds can also strongly alter the pharmacodynamics, e.g. the total uptake and distribution of the compound in the organs after its intake. Mostly, this is observable because of a big change in lipophilicity due to the different modifications. Especially for molecular imaging, where only defined structures in the body should be visualized, it is important to evaluate and optimize the effect of every modification (e.g. different spacer, chelator, coordinating metal) in this regard. Important points to be addressed regarding the applicability of the probes in standard procedures of diagnosis are the simplicity of production and the flexibility in the type of tracer that can be introduced. In the case of functionalization for surface coating, the strength and stability of the binding to the surface by the anchoring unit and the length and chemical structure of the spacer for a defined purpose (e.g. cell adhesion) has to be taken into account.

Molecules used as negative control in the determination of binding activities. For cellular and *in vitro* experiments, molecules with comparable steric properties and lipophilicity but without biological activity often serve as control compounds. Targeted substitution of any of the three amino acids in the RGD-sequence leads to inactivation of the ligand. A substitution of glycine by alanine leads to steric repulsions on the binding groove between the α - and β -subunit. Moreover, any elongation of the ligand (e.g. glycine to β -alanine and aspartate to glutamate substitution) leads to complete loss of binding activity. The molecules can be functionalized in the same way as their active biologically active counterparts (e.g. via lysine side chain). For this study, linear and cyclic control molecules have been synthesized and evaluated.

Conclusion

After the initial discovery of the RGD sequence in fibronectin, a large number of integrin ligands, binding to RGD-recognizing integrins, were developed by many groups around the world and became highly important for medical applications and for biophysical studies. For the development of each of these compounds, different evaluation techniques (e.g. various cell-based and cell free methods) have been used, allowing a good comparison and selection process of the compounds within a study. However, comparing the values determined by different groups for the very same compound shows very high deviations. For this reason we evaluated for the first time the most frequently used compounds in a homogenous solid phase binding assay for their binding affinity to six RGD-binding integrins ($\alpha\text{v}\beta\text{3}$, $\alpha\text{v}\beta\text{5}$, $\alpha\text{v}\beta\text{6}$, $\alpha\text{v}\beta\text{8}$, $\alpha\text{5}\beta\text{1}$, $\alpha\text{IIb}\beta\text{3}$). This gives the possibility to choose the ligand with the ideal affinity and selectivity pattern for a given application and opens new doors for the application of those ligands. However, the complex mechanism including several steps of conformational transitions in which the initial ligand binding to the resting state of the integrin and the stronger binding in the focal adhesion, might have consequences for the IC₅₀-value given here with data under different environmental condition *in vivo*¹⁰².

Methods Section

Integrin Binding Assay. The activity and selectivity of integrin ligands were determined by a solid-phase binding assay according to the previously reported protocol¹⁰³ using coated extracellular matrix proteins and soluble integrins. The following compounds were used as internal standards: **Cilengitide**, *c*(RGDf(NMe)V) ($\alpha\text{v}\beta\text{3}$ –0.54 nM, $\alpha\text{v}\beta\text{5}$ –8 nM, $\alpha\text{5}\beta\text{1}$ –15.4 nM), linear peptide **RTDLDSLRT**⁴ ($\alpha\text{v}\beta\text{6}$ –33 nM; $\alpha\text{v}\beta\text{8}$ –100 nM) and **tirofiban**⁵ ($\alpha\text{IIb}\beta\text{3}$ –1.2 nM).

Flat-bottom 96-well ELISA plates (BRAND, Wertheim, Germany) were coated overnight at 4 °C with the **ECM-protein (1)** (100 μL per well) in carbonate buffer (15 mM Na₂CO₃, 35 mM NaHCO₃, pH 9.6). Each well was then washed with PBS-T-buffer (phosphate-buffered saline/Tween20, 137 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, 2 mM KH₂PO₄, 0.01% Tween20, pH 7.4; 3 \times 200 μL) and blocked for 1 h at room temperature with TS-B-buffer (Tris-saline/BSA buffer; 150 μL /well; 20 mM Tris-HCl, 150 mM NaCl, 1 mM CaCl₂, 1 mM MgCl₂, 1 mM MnCl₂, pH 7.5, 1% BSA). In the meantime, a dilution series of the compound and internal standard is prepared in an extra plate, starting from 20 μM to 6.4 nM in 1:5 dilution steps. After washing the assay plate three times with PBS-T (200 μL), 50 μL of the dilution series were transferred to each well from B–G. Well A was filled with 100 μL TSB-solution (blank) and well H was filled with 50 μL TS-B-buffer. 50 μL of a solution of **human integrin (2)** in TS-B-buffer was transferred to wells H–B and incubated for 1 h at rt. The plate was washed three times with PBS-T buffer, and then **primary antibody (3)** (100 μL per well) was added to the plate. After incubation for 1 h at rt, the plate was washed three times with PBS-T. Then, **secondary peroxidase-labeled antibody (4)** (100 μL /well) was added to the plate and incubated for 1 h at rt. After washing the plate three times with PBS-T, the plate was developed by quick addition of SeramunBlau (50 μL per well, Seramun Diagnostic GmbH, Heidesee, Germany) and incubated for 5 min at rt in the dark. The reaction was stopped with 3 M H₂SO₄ (50 μL /well), and the absorbance was measured at 450 nm with a plate reader (POLARstar Galaxy, BMG Labtechnologies). The IC₅₀ of each compound was tested in duplicate, and the resulting inhibition curves were analyzed using OriginPro 7.5G software. The inflection point describes the IC₅₀ value. All determined IC₅₀ were referenced to the activity of the internal standard.

$\alpha\text{v}\beta\text{3}$

- (1) 1.0 $\mu\text{g}/\text{mL}$ human vitronectin; Millipore.
- (2) 2.0 $\mu\text{g}/\text{mL}$, human $\alpha\text{v}\beta\text{3}$ -integrin, R&D.
- (3) 2.0 $\mu\text{g}/\text{mL}$, mouse anti-human CD51/61, BD Biosciences.
- (4) 1.0 $\mu\text{g}/\text{mL}$, anti-mouse IgG-POD, Sigma-Aldrich.

$\alpha 5\beta 1$

- (1) 0.5 $\mu\text{g}/\text{mL}$; human fibronectin, Sigma-Aldrich.
- (2) 2.0 $\mu\text{g}/\text{mL}$, human $\alpha 5\beta 1$ -integrin, R&D.
- (3) 1.0 $\mu\text{g}/\text{mL}$, mouse anti-human CD49e, BD Biosciences.
- (4) 2.0 $\mu\text{g}/\text{mL}$, anti-mouse IgG-POD, Sigma-Aldrich.

 $\alpha v\beta 5$

- (1) 5.0 $\mu\text{g}/\text{mL}$; human vitronectin, Millipore.
- (2) 3.0 $\mu\text{g}/\text{mL}$, human $\alpha v\beta 5$ -integrin, Millipore.
- (3) 1:500 dilution, anti- αv mouse anti-human MAB1978, Millipore.
- (4) 1.0 $\mu\text{g}/\text{mL}$, anti-mouse IgG-POD, Sigma-Aldrich.

 $\alpha v\beta 6$

- (1) 0.4 $\mu\text{g}/\text{mL}$; LAP (TGF- β), R&D.
- (2) 0.5 $\mu\text{g}/\text{mL}$, human $\alpha v\beta 6$ -Integrin, R&D.
- (3) 1:500 dilution, anti- αv mouse anti-human MAB1978, Millipore.
- (4) 2.0 $\mu\text{g}/\text{mL}$, anti-mouse IgG-POD, Sigma-Aldrich.

 $\alpha v\beta 8$

- (1) 0.4 $\mu\text{g}/\text{mL}$; LAP (TGF-b), R&D.
- (2) 0.5 $\mu\text{g}/\text{mL}$, human $\alpha v\beta 8$ -Integrin, R&D.
- (3) 1:500 dilution, anti- αv mouse antihuman MAB1978, Millipore.
- (4) 2.0 $\mu\text{g}/\text{mL}$, anti-mouse IgG-POD, Sigma-Aldrich.

 $\alpha \text{IIb}\beta 3$

- (1) 10.0 $\mu\text{g}/\text{mL}$; human fibrinogen, Sigma-Aldrich.
- (2) 5.0 $\mu\text{g}/\text{mL}$, human platelet integrin $\alpha \text{IIb}\beta 3$, VWR.
- (3) 2.0 $\mu\text{g}/\text{mL}$, mouse anti-human CD41b, BD Biosciences.
- (4) 1.0 $\mu\text{g}/\text{mL}$, anti-mouse IgG-POD, Sigma-Aldrich.

References

1. Hynes, R. O. & Naba, A. Overview of the matrisome - an inventory of extracellular matrix constituents and functions. *Cold Spring Harb. Perspect Biol.* **4**, a004903 (2012).
2. Frantz, C., Stewart, K. M. & Weaver, V. M. The extracellular matrix at a glance. *J. Cell Sci.* **123**, 4195–4200 (2010).
3. Juliano, R. L. Signal transduction by cell adhesion receptors and the cytoskeleton: functions of integrins, cadherins, selectins, and immunoglobulin-superfamily members. *Annu. Rev. Pharmacol. Toxicol.* **42**, 283–323 (2002).
4. Geiger, B., Spatz, J. P. & Bershadsky, A. D. Environmental sensing through focal adhesions. *Nat. Rev. Mol. Cell Biol.* **10**, 21–33 (2008).
5. Pierschbacher, M. D. & Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. *Nature* **309**, 30–33 (1984).
6. Meyer, A., Auernheimer, J., Modlinger, A. & Kessler, H. Targeting RGD Recognizing Integrins: Drug Development, Biomaterial Research, Tumor Imaging and Targeting. *Curr. Pharmaceutical Design* **12** 2723–2747 (2006).
7. Sheldrake, H. M. & Patterson, L. H. Strategies To Inhibit Tumor Associated Integrin Receptors: Rationale for Dual and Multi-Antagonists, *J. Med. Chem.* **57**, 6301–6315 (2014).
8. Auzzas, L. *et al.* Targeting alphavbeta3 integrin: design and applications of mono- and multifunctional RGD-based peptides and semipeptides. *Curr. Med. Chem.* **17**, 1255–1299 (2010).
9. Shimaoka, M. & Springer, T. A. Therapeutic antagonists and conformational regulation of integrin function. *Nat. Rev. Drug Discov.* **2**, 703–716 (2003).
10. Plow, E. F., Haas, T. A., Zhang, L., Loftus, J. & Smith, J. W. Ligand Binding to Integrins, *J. Biol. Chem.* **275**, 21785–21788 (2000).
11. Takada, Y., Ye, X. & Simon, S. The integrins. *Genome Biology* **8**, 215 (2007).
12. Mould, A. P. & Humphries, M. J. Cell biology - adhesion articulated. *Nature* **432**, 27–28 (2004).
13. Marelli, U. K., Rechenmacher, F., Ali Sobahi, T. R., Mas-Moruno, C. & Kessler, H. Tumor targeting via integrin ligands, *Front. Oncol.* **3**, 222 (2013).
14. Cox, D., Brennan, M. & Moran, N. Integrins as therapeutic targets: lessons and opportunities. *Nat. Rev. Drug Disc.* **9**, 804–820 (2010).
15. Ley, K., Rivera-Nieves, J., Sandborn, W. J. & Shattil, S. Integrin-based therapeutics: biological basis, clinical use and new drugs biological basis, clinical use and new drugs. *Nat. Rev. Drug Discov.* **15**, 173–183 (2016).
16. Goodman, S. L. & Picard, M. Integrins as therapeutic targets. *Trends Pharmacol. Sci.* **33**, 405–412 (2012).
17. Kapp, T. G., Rechenmacher, F., Sobahi, T. R. & Kessler, H. Integrin modulators: a patent review. *Expert Opin. Ther. Pat.* **23**, 1273–1295 (2013).
18. Degrosellier, J. S. & Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities. *Nat. Rev. Cancer* **10**, 9–22 (2010).
19. Hamilton, A. M. *et al.* Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain. *J. Mol. Med.* **93**, 991–1001 (2015).
20. Schottelius, M., Laufer, B., Kessler, H. & Wester, H.-J. Ligands for mapping $\alpha v\beta 3$ -integrin expression *in vivo*. *Acc. Chem. Res.* **42**, 969–980 (2009).

21. Plotnikov, S. V., Pasapera, A. M., Sabass, B. & Waterman, C. M. Force fluctuations within focal adhesions mediate ECM-rigidity sensing to guide directed cell migration. *Cell* **151**, 1513–27 (2012).
22. Hersel, U., Dahmen, C. & Kessler, H. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. *Biomaterials* **24**, 4385–4415 (2003).
23. Arnold, M. *et al.* Activation of Integrin Function by Nanopatterned Adhesive Interfaces. *ChemPhysChem* **3**, 383–388 (2004).
24. Mas-Moruno, C. *et al.* $\alpha\text{v}\beta 3$ - or $\alpha 5\beta 1$ -Integrin-Selective Peptidomimetics for Surface Coating. *Angew. Chem. Int. Ed.* **55**, 7048–7067 (2016).
25. Pfaff, M. *et al.* Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. *J. Biol. Chem.* **269**, 20233–20238 (1994).
26. Aumailley, M. *et al.* Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. *FEBS Lett.* **291**, 50–54 (1991).
27. Kessler, H., Gratias, R., Hessler, G., Gurrath, M. & Müller, G. Conformation of cyclic peptides. Principle concepts and the design of selectivity and superactivity in bioactive sequences by 'spatial screening'. *Pure & Appl. Chem.* **68**, 1201–1205 (1996).
28. Weide, T., Modlinger, A. & Kessler, H. Spatial Screening for the Identification of the Bioactive Conformation of Integrin Ligands; *Topics in Current Chemistry* **272**, 1–50 (2007).
29. Müller, G., Gurrath, M. & Kessler, H. Pharmacophore refinement of gpIIb/IIIa antagonists based on comparative studies of antiadhesive cyclic and acyclic RGD peptides; *J. Comp-Aided Mol. Design* **8**, 709–730 (1994).
30. Dechantsreiter, M. A. *et al.* N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. *J. Med. Chem.* **42**, 3033–3040 (1999).
31. Mas-Moruno, C., Rechenmacher, F. & Kessler, H. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. *Anticancer Agents Med. Chem.* **10**, 753–768 (2010).
32. Zhu, J. *et al.* Structure of a complete integrin ectodomain in a physiologic resting state and activation and deactivation by applied forces. *Mol. Cell* **32**, 849–861 (2008).
33. Xiong, J. P. *et al.* Crystal structure of the extracellular segment of integrin alphavbeta3. *Science* **294**, 339–345 (2001).
34. Marelli, U. K. *et al.* The Solution Conformation of Cilengitide Represents the Receptor Bound Conformation better than the X-Ray Structure of Cilengitide. *Chemistry Eur. J.* **20**, 14201–14206 (2014).
35. Heckmann, D. *et al.* Probing Integrin Selectivity: Rational Design of Highly Active and Selective Ligands for the $\alpha 5\beta 1$ and $\alpha \text{v}\beta 3$ Integrin Receptor. *Angew. Chem. Int. Ed.* **46**, 3571–3574 (2007).
36. Stragies, R. *et al.* Design and synthesis of a new class of selective integrin $\alpha 5\beta 1$ antagonists. *J. Med. Chem.* **50**, 3786–3794 (2007).
37. Neubauer, S. *et al.* Pharmacophoric Modifications Lead to Superpotent $\alpha \text{v}\beta 3$ Integrin Ligands with Suppressed $\alpha 5\beta 1$ Activity; *J. Med. Chem.* **57**, 3410–3417 (2014).
38. Maltsev, O. V. *et al.* Stable Peptides Instead of Stapled Peptides: Highly Potent $\alpha \text{v}\beta 6$ -Selective Integrin Ligands. *Angew. Chem. Int. Ed.* **55**, 1535–1538 (2016).
39. Rechenmacher, F. *et al.* Functionalizing $\alpha \text{v}\beta 3$ - or $\alpha 5\beta 1$ -selective integrin antagonists for surface coating: a method to discriminate integrin subtypes *in vitro*. *Angew. Chem. Int. Ed. Engl.* **52**, 1572–1575 (2013).
40. Rechenmacher, F. *et al.* A molecular toolkit for the functionalization of titanium-based biomaterials that selectively control integrin-mediated cell adhesion. *Chemistry* **19**, 9218–9223 (2013).
41. Xiong, J. P. *et al.* Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. *Science* **296**, 151–155 (2002).
42. Marinelli, L. *et al.* Ligand Binding Analysis for Human $\alpha 5\beta 1$ Integrin: Strategies for Designing New $\alpha 5\beta 1$ Integrin Antagonists. *J. Med. Chem.* **48**, 4204–4207 (2005).
43. Marinelli, L., Lavecchia, A., Gottschalk, K. E., Novellino, E. & Kessler, H. Docking Studies on $\alpha \text{v}\beta 3$ Integrin Ligands: Pharmacophore Refinement and Implications for Drug Design; *J. Med. Chem.* **46**, 4393–4404 (2003).
44. Heckmann, D. *et al.* Breaking the dogma of the metal-coordinating carboxylate group in integrin ligands: introducing hydroxamic acids to the MIDAS to tune potency and selectivity. *Angew. Chem. Int. Ed.* **48**, 4436–4440 (2009).
45. Nagae, M. *et al.* Crystal structure of $\alpha 5\beta 1$ integrin ectodomain: atomic details of the fibronectin receptor. *J. Cell Biol.* **187**, 131–140 (2012).
46. Kapp, T. G., Fottner, M., Maltsev, O. V. & Kessler, H. Small Cause, Great Impact: Modification of the Guanidine Group in the RGD Motif Controls Integrin Subtype Selectivity. *Angew. Chem. Int. Ed. Engl.* **55**, 1540–1543 (2016).
47. Margadant, C. & Sonnenberg, A. Integrin-TGF- β crosstalk in fibrosis, cancer and wound healing. *EMBO reports* **11**, 97–105 (2010).
48. Friedlander, M. *et al.* Definition of two angiogenic pathways by distinct alpha v integrins. *Science* **270**, 1500–1502 (1995).
49. Goodman, S. L., Hölzemann, G., Sulyok, G. A. & Kessler, H. Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins. *J. Med. Chem.* **45**, 1045–1051 (2002).
50. Mas-Moruno, C. *et al.* Increasing $\alpha \text{v}\beta 3$ selectivity of the anti-angiogenic drug cilengitide by N-methylation. *Angew. Chem. Int. Ed.* **50**, 9496–9500 (2011).
51. Assa-Munt, N., Jia, X., Laakkonen, P. & Ruoslahti, E. Solution Structures and Integrin Binding Activities of an RGD Peptide with Two Isomers. *Biochemistry* **40**, 2373–2378 (2001).
52. Bochen, A. *et al.* Biselectivity of isoDGR peptides for fibronectin binding integrin subtypes $\alpha 5\beta 1$ and $\alpha \text{v}\beta 6$: conformational control through flanking amino acids. *J. Med. Chem.* **56**, 1509–1519 (2013).
53. Maguire, J. J., Kuc, R. E. & Davenport, A. P. Radioligand binding assays and their analysis. *Methods Mol. Biol.* **897**, 31–77 (2012).
54. Mousa, S. A. & Mohamed, S. Human alphavbeta3 integrin potency and specificity of TA138 and its DOTA conjugated form (89) Y-TA138. *J. Cardiovasc. Pharmacol.* **45**, 109–113 (2005).
55. Liu, S. *et al.* PET Imaging of Integrin Positive Tumors Using F Labeled Knottin Peptides. *Theranostics* **1**, 403–412 (2011).
56. van der Flier, A. *et al.* Endothelial alpha5 and alphav integrins cooperate in remodeling of the vasculature during development. *Development* **137**, 2439–2449 (2010).
57. Frank, A. O. *et al.* Conformational Control of Integrin-Subtype Selectivity in isoDGR Peptide Motifs: A Biological Switch. *Angew. Chem. Int. Ed.* **49**, 9278–9281 (2010).
58. Gan, Z. R., Gould, R. J., Jacobs, J. W., Friedman, P. A. & Polokoff, M. A. Echistatin – A potent platelet aggregation inhibitor from the venom of the viper, *Echis Carinatus*. *J. Biol. Chem.* **263**, 19827–19832 (1988).
59. Pfaff, M., McLane, M. A., Beviglia, L., Niewiarowski, S. & Timpl, R. Comparison of Disintegrins with limited variation in the RGD Loop in their binding to purified integrins $\alpha \text{IIb}\beta 3$, $\alpha \text{v}\beta 3$ and $\alpha 5\beta 1$ and in cell adhesion inhibition. *Cell Adhes. Commun.* **2**, 491–501 (1994).
60. Zheng, Y., Ji, S., Tomaselli, E., Yang, Y. & Liu, S. Comparison of biological properties of (111)In-labeled dimeric cyclic RGD peptides. *Nucl. Med. Biol.* **42**, 137–145 (2015).
61. Durkan, K. *et al.* A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] $\alpha \text{v}\beta 3$ /GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors. *Nucl. Med. Biol.* **41**, 133–139 (2014).
62. Pytela, R., Pierschbacher, M. D., Ginsberg, M. H., Plow, E. F. & Ruoslahti, E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp-specific adhesion receptors. *Science* **231**, 1559–1562 (1986).

63. Mogford, J. E., Davis, G. E. & Meininger, G. A. RGDN Peptide Interaction with Endothelial $\alpha 5 \beta 1$ Integrin Causes Sustained Endothelin-dependent Vasoconstriction of Rat Skeletal Muscle Arterioles, *J. Clin. Invest.* **100**, 1647–1653 (1997).
64. Dedhar, S., Ruoslahti, E. & Pierschbacher, M. D. A Cell Surface Receptor Complex for Collagen Type I Recognizes the Arg-Gly-Asp Sequence. *J. Cell. Biol.* **104**, 585–593 (1987).
65. Bogdanowich-Knipp, S. J., Chakrabarti, S., Siahaan, T. J., Williams, T. D. & Dillman, R. K. Solution stability of linear vs. cyclic RGD peptides. *J. Pep. Res.* **53**, 530–541 (1999).
66. Chatterjee, J. *et al.* Multiple N-Methylation by a Designed Approach Enhances Receptor Selectivity. *J. Med. Chem.* **50**, 5878–5881 (2007).
67. Kessler, H. Conformation and Biological Activity of Cyclic Peptides; *Angew. Chem. Int. Ed. Engl.* **21**, 512–523 (1982).
68. Haubner, R., Gratias, R., Diefenbach, B., Goodman, S. L., Jonczyk, A. & Kessler, H. Structural and Functional Aspects of RGD-Containing Cyclic Pentapeptides as Highly Potent and Selective Integrin $\alpha \nu \beta 3$ Antagonists. *J. Am. Chem. Soc.* **118**, 7461–7472 (1996).
69. Haubner, R., Finsinger, D. & Kessler, H. Stereoisomeric Peptide Libraries and Peptidomimetics for Designing Selective Inhibitors of the $\alpha \nu \beta 3$ Integrin for a New Cancer Therapy. *Angew. Chem. Int. Ed.* **36**, 1374–1389 (1997).
70. Becker, A. *et al.* Metabolism and Disposition of the $\alpha \nu$ -Integrin $\beta 3 / \beta 5$ Receptor Antagonist Cilengitide, a Cyclic Polypeptide, in Humans. *The Journal of Clinical Pharmacology* **55**, 815–824 (2015).
71. Stupp, R. *et al.* Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071–22072 study): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol.* **15**, 1100–1108 (2014).
72. Nabors, L. B. *et al.* Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. *Neuro Oncol.* **17**, 708–715 (2015).
73. Tucci, M. *et al.* Cilengitide restrains the osteoclast-like bone resorbing activity of myeloma plasma cells. *Brit. J. Haematol.* **173**, 59–69 (2016).
74. Ewan, C. & March, J. Patent PCT/GB2015/053215.
75. Alva, A. *et al.* Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. *Invest. New Drugs* **30**, 749–757 (2012).
76. Kantlehner, M. *et al.* Selective RGD-Mediated Adhesion of Osteoblasts at Surfaces of Implants. *Angew. Chem. Int. Ed.* **38**, 560–562 (1999).
77. Kantlehner, M. *et al.* Surface Coating with Cyclic RGD Peptides Stimulates Osteoblast Adhesion and Proliferation as well as Bone Formation. *ChemBioChem* **1**, 107–114 (2000).
78. Lopez-Rodriguez, V. *et al.* Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))₂ as a potential theranostic radiopharmaceutical. *Nucl Med Biol.* **42**, 109–114 (2015).
79. Garanger, E., Boturn, D. & Dumy, P. Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. *Anticancer Agents Med Chem.* **7**, 552–558 (2007).
80. Brooks, P. C. *et al.* Integrin $\alpha \nu \beta 3$ antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. *Cell* **79**, 1157–1164 (1994).
81. Prante, O. *et al.* 3,4,6-Tri-O-acetyl-2-deoxy-2-[18F]fluoroglucopyranosyl phenylthiosulfonate: a thiol-reactive agent for the chemoselective 18F-glycosylation of peptides. *Bioconjugat. Chem.* **18**, 254 (2007).
82. Koivunen, E., Wang, B. & Ruoslahti, E. Phage Libraries Displaying Cyclic Peptides with Different Ring Sizes: Ligand Specificities of the RGD-Directed Integrins *Nature Biotechnology* **13**, 265–270 (1995).
83. Smolarczyk, R. *et al.* Antitumor effect of RGD-4C-GG-D(KLAKLAK)₂ peptide in mouse B16(F10) melanoma model. *Acta Biochim. Pol.* **53**, 801–805 (2006).
84. Hölig, P. *et al.* Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells. *Protein Eng. Des. Sel.* **17**, 433–441 (2004).
85. Indrevoll, A. *et al.* NC-100717: A versatile RGD peptide scaffold for angiogenesis imaging. *Bioorg. Med. Chem. Lett.* **16**, 6190–6193 (2006).
86. Kenny, L. M. *et al.* Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand 18F-AH111585 in Breast Cancer Patients. *J. Nucl. Med.* **49**, 879–886 (2008).
87. Trivedi, M. V., Laurence, J. S. & Siahaan, T. J. The role of thiols and disulfides in protein chemical and physical stability. *Curr. Protein Pept. Sci.* **10**, 614–625 (2009).
88. Curnis, F. *et al.* Spontaneous formation of l-isoaspartate and gain of function in fibronectin. *J. Biol. Chem.* **281**, 36466–36476 (2006).
89. Takahashi, S. *et al.* The RGD motif in fibronectin is essential for development but dispensable for fibril assembly. *J. Cell Biol.* **178**, 167–178 (2007).
90. Stoeltzing, O. *et al.* Inhibition of integrin $\alpha 5 \beta 1$ function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. *Int. J. Cancer* **104**, 496–503 (2003).
91. Heckmann, D. *et al.* Rational Design of Highly Active and Selective Ligands for the $\alpha 5 \beta 1$ Integrin Receptor. *ChemBioChem* **9**, 1397–1407 (2008).
92. Neubauer, S. *et al.* Selective imaging of the angiogenic relevant integrins $\alpha 5 \beta 1$ and $\alpha \nu \beta 3$. *Angew. Chem. Int. Ed.* **52**, 11656–11659 (2013).
93. Kraft, S. *et al.* Definition of an unexpected ligand recognition motif for $\alpha \nu \beta 6$ integrin. *J. Biol. Chem.* **274**, 1979–1985 (1999).
94. DiCara, D. *et al.* Structure-Function Analysis of Arg-Gly-Asp Helix Motifs in $\alpha \nu \beta 6$ Integrin Ligands. *J. Biol. Chem.* **282**, 9657–9665 (2007).
95. Scarborough R. M., Naughton M. A., Teng W. *et al.* Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. *J Biol Chem* **268**, 1066–73 (1993).
96. Hartman, G. D. *et al.* Non-peptide fibrinogen receptor antagonists. Discovery and design of exosite inhibitors. *J. Med. Chem.* **35**, 4640–4642 (1992).
97. Eldred, C. D. *et al.* Orally active non-peptide fibrinogen receptor (GpIIb/IIIa) antagonists: identification of 4-[4-[4-(aminoiminomethyl)phenyl]-1-piperazinyl]-1-piperidineacetic acid as a long-acting, broad spectrum antithrombotic agent. *J. Med. Chem.* **37**, 3882–3885 (1994).
98. Liese, S. & Netz, R. R. Influence of length and flexibility of spacers on the binding affinity of divalent ligands. *Beilstein J. Org. Chem.* **11**, 804–816 (2015).
99. Pallarola, D. *et al.* Interface Immobilization Chemistry of cRGD-based Peptides Regulates Integrin Mediated Cell Adhesion. *Adv. Funct. Mat.* **24**, 943–956 (2014).
100. Haubner, R. *et al.* Noninvasive Visualization of the Activated $\alpha \nu \beta 3$ Integrin in Cancer Patients by Positron Emission Tomography and [¹⁸F]Galacto-RGD. *PLoS Medicine* **2**, 244–252 (2005).
101. Šimeček, J. *et al.* Benefits of NOPO As Chelator in Gallium-68 Peptides, Exemplified by Preclinical Characterization of ⁶⁸Ga-NOPO-c(RGDfK). *Mol. Pharm.* **11**, 1687–1695 (2014).

102. Müller, M. A. *et al.* The glycoporphin A transmembrane sequence within integrin $\alpha v\beta 3$ creates a non-signalling integrin with low basal affinity that is strongly adhesive under force. *J. Mol. Biol.* **425**, 2988–3006 (2013).
103. Frank, A. O., Otto, E., Mas-Moruno, C., Schiller, H. B., Marinelli, L., Cosconati, S., Bochen, A., Vossmeier, D., Zahn, G., Stragies, R., Novellino, E. & Kessler, H. *Angew. Chem. Int. Ed.* **2010**, *49*, 9278–9281.

Acknowledgements

We thank the company GE for providing us with samples of *Fluciclatide* and *NC100717*, the company 3B Pharmaceuticals for samples of *JSM6427* and Prof. Corti and Dr. Curnis for providing us with a sample of *A20FMDV2*. T.G.K. acknowledges the International Graduate School for Science and Engineering (IGSSE) of the Technische Universität München (TUM) for financial support. BG is the Erwin Neter Professor in cell and Tumor Biology. HK is Carl von Linde Professor at the Institute for Advanced Study. Financial support by the Deutsche Forschungsgemeinschaft and the Center of Integrated Protein Science Munich (CIPSM) is gratefully acknowledged.

Author Contributions

T.G.K., R.Z., C.M.-M., B.G., J.S. and H.K. wrote the manuscript, T.G.K., F.R. and O.V.M. performed the experiments, T.G.K., F.R., S.N., O.V.M., A.E.C.-A., U.R., J.N., C.M.-M., H.-J.W. and H.K. analyzed the data, T.G.K., F.R., J.S., B.G. and H.K. designed the study, all authors read and revised the manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Kapp, T. G. *et al.* A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins. *Sci. Rep.* **7**, 39805; doi: 10.1038/srep39805 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2017